Evidence map›Paper›PMID 41300197›Full record

ReviewBrain sciences2025

A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder.

A Benjamin Srivastava, Mark S Gold

Abstract readReview
In one paragraph

Review in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

A Benjamin SrivastavaDepartment of Psychiatry, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0001-9358-7506
Mark S GoldDepartment of Psychiatry, Washington University School of Medicine, Saint Louis, MO 63110, USA.

Funding

Neural mechanisms of anxiety during early and protracted abstinence in alcohol use disorderK23AA030355 · NIAAA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI A B Srivastava · 2024 to 2026
$583k
NIAAA NIH HHS K23 AA030355NIH HHS 1K23AA030355-02
6 · The paper itself

Abstract

The past two decades have seen the reemergence of research investigating the therapeutic potential of psychedelic drugs across neuropsychiatric illnesses. One condition, alcohol use disorder (AUD), is of relevance given the broad public health implications and both limited effectiveness and attrition associated with currently available treatments. While emerging research has suggested that the benefits of psychedelic drugs in the treatment of AUD may be considerable, several fundamental aspects of this work limit the conclusions that can be drawn. These limitations include those that apply to research involving psychedelics generally-including functional unblinding and the role and definition of "psychedelic assisted psychotherapy" and some unique to AUD, including the nature of the mystical experience and how it relates to the "spiritual experience" as described in the literature of Alcoholics Anonymous (AA), of which the history of psychedelic research in AUD is closely intertwined. Additionally, current mechanistic neuroimaging studies examining the therapeutic effects of psychedelics in AUD are limited by design and do not directly interrogate the cognitive and circuit-level processes likely underlying treatment response. This review describes these limitations in detail by bridging historical, conceptual, and mechanistic aspects of psychedelic research in AUD and offers suggestions for future studies, the results of which may more clearly specify the role and utility of psychedelic drugs in the treatment of AUD.

Indexed as

alcoholics anonymousalcohol use disordercognitive controldorsolateral prefrontal cortexpsilocybinpsychedelic

Identifiers

PMID41300197
PMCPMC12650486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.